Partner Institutions
CUREVERSE possesses infrastructure for basic research and clinical expertise.
By forming a collaborative research network involving
Korea’s top academia–industry–research–hospital sectors
and global partners,
we accelerate the development of new drugs
for intractable diseases.
Licensing Partner
A global pharmaceutical company specializing in brain diseases
- CV-01 : Non-clinical and global clinical development
- CV-01 : Global commercialization
Angelini Pharma
Angelini Pharma, founded in 1919 in Ancona, Italy, is a pharmaceutical company with world-class research and development capabilities in the fields of mental health and neurology.
Its flagship product is the antidepressant Trittico®, and it supplies pharmaceutical products to over 70 countries worldwide.
University Medical Center Göttingen
& CNRS Bordeaux
Prof. Dr. Valentin Nägerl
(Institute Director, Institute of Anatomy
& Cell Biology, Göttingen Univ. Medical Center)
- World-renowned researcher in the field of Neuroscience and Bioimaging
- Leading research on synaptic plasticity and super-resolution brain imaging (STED, 2P-STED)
Synapse and neural plasticity research
Super-resolution brain imaging technology
Elucidation of neurological disease mechanisms
KIST (Korea Institute of Science & Technology)
Dr. Bae Ae-nim
Brain Science Institute
(Former) Director of the Dementia DTC Convergence Research Division
Dr. Kim Yoon-kyung
Brain Science Institute
Principal Researcher
- Technology for developing therapeutics for intractable brain diseases
- Establishment of efficacy and biomarker evaluation systems for brain diseases
Customized Drug Development for Brain Diseases
Efficacy Evaluation
Target Discovery Technology
Biomarker Verification for Therapeutics
IBS (Institute for Basic Science)
& KIT (Korea Institute of Toxicology)
Dr. Chang-Joon Lee
(Director, Cognitive and Social Behavior Research Group)
- Expert in biomarkers for dementia and neuropsychiatric disorders
- Evaluation of PK and toxicity using non-human primate models
Dementia Biomarkers
Non-Human Primate-Based Research
Dementia Mechanism Research
GLP Nonclinical Studies
SNUH (Seoul National University Hospital)
& SCH (Soonchunhyang University Hospital)
Professor
Kim Sung-min
Department of Neurology, Seoul National University Hospital
Professor
Lee Eun-young
Department of Nephrology, Soonchunhyang University Hospital
- Establishment of collaborative research infrastructure with hospital-based clinical experts
Seoul National University Neurology
Clinical Expert in Brain Disorders
Soonchunhyang University Nephrology
KNUH (Kyungpook National University Hospital)
& KMEDIhub (Daegu-Gyeongbuk Medical Innovation Foundation)
Professor
Lee In-kyu
Kyungpook National University Hospital
(Former Head of the Advanced New Drug Development Project Group)
KMEDlhub
(Preclinical Center, Drug Optimization)
- Establishment of clinical-driven translational drug development research infrastructure
- Specialized new drug development institution
Specialized Synthesis Technology
Preclinical Animal Center
Applied Translational Drug Development
ADME/Tox Evaluation
Yonsei University
Professor
Joon-Young Hong
Department of Systems Biology Expert in immune-oncology research
Professor
Hye-Jin Kang
Department of Biological Engineering Innovative drug development utilizing chemical genetics and molecular pharmacology
- Establishing scientific evidence for new drug candidates through basic research and in vivo efficacy validation
Basic Research
In-Vivo Efficacy Validation
New Drug Candidates
SNUH (Seoul National University Hospital)
Clinical Trials Center
A specialized clinical research institute
- Possesses top-tier clinical trial capabilities in Korea
- Collaborates in new drug development based on scientific and safety standards
